Neurizon Therapeutics Ltd. engages in the business of developing own drug discovery intellectual property for the treatment of different types of cancers, neurological diseases, and viral infections; and providing highly specialized medicinal and synthetic chemistry services on a contract basis to clients. It operates under the Corporate and Research, and Pharmaceutical-Epichem segments. The Corporate and Research segment includes corporate overhead expenses. The Pharmaceutical-Epichem segment provides products and services in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries. The company was founded on December 2003 and is headquartered in Claremont, Australia.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Neurizon Therapeutics Ltd.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Neurizon Therapeutics Ltd. market cap is $72.17M.
What is the 52-week high for Neurizon Therapeutics Ltd.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Neurizon Therapeutics Ltd. 52 week high is $0.10 as of October 22, 2025.
What is the 52-week low for Neurizon Therapeutics Ltd.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Neurizon Therapeutics Ltd. 52 week low is $0.0686 as of October 22, 2025.
What is Neurizon Therapeutics Ltd. stock price today?
Neurizon Therapeutics Ltd. stock price today is $0.0686.
What was Neurizon Therapeutics Ltd. stock price yesterday?
Neurizon Therapeutics Ltd. stock price yesterday was $0.07.
What is the PE ratio of Neurizon Therapeutics Ltd.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Neurizon Therapeutics Ltd.’s P/E ratio is -3.12.
What is the Price-to-Book ratio of Neurizon Therapeutics Ltd.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Neurizon Therapeutics Ltd. P/B ratio is 18.2933.
What is the 50-day moving average of Neurizon Therapeutics Ltd.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Neurizon Therapeutics Ltd. 50-day moving average is $0.011.